Since the beginning of the epidemic, there have been significant reductions in mother-to-child transmission of HIV in the U.S. Research has also shown that progress is possible through targeted prevention programs that are effective in reducing risky behaviors among HIV-positive and HIV-negative women.
Bristol-Myers Squibb ( BMY) and Pfizer ( PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.
In the past several years, one of the most respected institutions in the area of disease prevention has come under scrutiny for allowing its assessments to be colored by a bias toward positive results and to be swayed by advocacy in the wider society.